Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD

Daniel M. Strickland; Jordon T. Baker

doi:10.5055/jom.2023.0807

Authors

Daniel M. Strickland, MS, MD, FACOG https://orcid.org/0000-0001-8684-9184
Jordon T. Baker, PharmD

DOI:

https://doi.org/10.5055/jom.2023.0807

Keywords:

buprenorphine, naloxone, pharmacy, regulation, intolerance

Abstract

Introduction: Buprenorphine (BUP) is increasingly recognized and utilized as a valuable medication for the treatment of opioid use disorder. This article focuses on the problem of regulatory restrictions on access to buprenorphine products without naloxone (mono-product), involving patients in one geographic area, but which may represent a more general access problem in the United States.

Design: In response to an audit by the Tennessee Board of Pharmacy, a pharmacy in northeast Tennessee designed a questionnaire to survey patient motivation for traveling long distances to fill their prescriptions for BUP, rather than buprenorphine/ naloxone (BNx, combo-product), and to document their satisfaction with treatment with the mono-product.

Results: Questionnaires were submitted by 194 patients, living in northeast Tennessee, southwest Virginia, and southeast Kentucky. Significant, intolerable, side effects were reported by all patients in the survey prescribed BNx, but because of legislative and regulatory restrictions in their respective states, they were unable to obtain BUP closer to home. Consequently, they were required to drive significant distances from their homes to fill their prescriptions, a median distance of 52 miles, and in some cases as far as 216 miles round trip. Intolerable reactions included severe headaches, nausea and vomiting, allergies, and severe dysphoria. All patients tolerated BUP and were clinically well maintained on the mono-product.

Conclusion: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.

Author Biographies

Daniel M. Strickland, MS, MD, FACOG

WJ Medical Associates, Warrensville, North Carolina

Jordon T. Baker, PharmD

Roan Mountain Pharmacy, Roan Mountain, Tennessee

References

Poliwoda S, Noor N, Jenkins JS, et al.: Buprenorphine and its formulations: A comprehensive review. Health Psychol Res. 2022; 10(3): 37517. DOI: https://doi.org/10.52965/001c.37517

Bridge TP, Fudala PJ, Herbert S, et al.: Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 2003; 70(2 Suppl): S79-S85. DOI: https://doi.org/10.1016/S0376-8716(03)00061-9

Strickland DM, Gale G: Buprenorphine and drug overdose deaths. Ann Clin Toxicol. 2022; 5(1): 1036.

American Society of Addiction Medicine: Public policy statement on morphine equivalent units/morphine milligram equivalents (PDF File). Available at https://bit.ly/3D5dT9z. Accessed July 9, 2023.

Knauth D: Walgreens reaches $683 million opioid settlement with Florida. Reuters. 2022; 5. Available at https://reut.rs/3ImVBTM. Accessed July 9, 2023.

Stempel J: Walgreens reaches $230 million opioid settlement with San Francisco. Reuters. 2023; 17. Available at https://reut.rs/43b3hAn. Accessed July 9, 2023.

Syros A, Rodriguez MG, Rennick AC, et al.: Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: A secret shopper survey. Addict Sci Clin Prac. 2022; 17: 63. DOI: https://doi.org/10.1186/s13722-022-00346-x

Dadiomov D, Bolshakova M, Mikhaeilyan M, et al.: Buprenorphine and naloxone access in pharmacies within high overdose area of Los Angeles during the COVID-19 pandemic. Harm Reduct J. 2022; 19: 69. Available at https://rdcu.be/c4lV5. Accessed 29 July, 2023. DOI: https://doi.org/10.1186/s12954-022-00651-3

Carpenter D, Lambert KV, Harless JC, et al.: North Carolina community pharmacists' buprenorphine dispensing practices and attitudes. J Am Pharm Assoc: Sci Practice Res. 2022; 62(4): 1606-1614. DOI: https://doi.org/10.1016/j.japh.2022.04.019

Winstanley EL, Thacker EP, Yuen Choo L, et al.: Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use. Drug Alcohol Depend Rep. 2022; 5: 100091. DOI: https://doi.org/10.1016/j.dadr.2022.100091

Welsh J, Yarbrough C, Sitar S, et al.: Demographic and socioeconomic correlates to buprenorphine access in pharmacies. J Am Pharm Assoc. 2022; 63(3): 751-759. DOI: https://doi.org/10.1016/j.japh.2022.12.015

Kazerouni NJ, Irwin AN, Levander XA, et al.: Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021; 224: 108729. DOI: https://doi.org/10.1016/j.drugalcdep.2021.108729

Cooper HLF, Cloud DH, Young AM, et al.: When prescribing isn't enough—Pharmacy-level barriers to buprenorphine access. N Engl J Med. 2020; 383(8): 703-705. DOI: https://doi.org/10.1056/NEJMp2002908

Bratberg J, Falleni A: Preserving dignity through expanded and sustained access to buprenorphine. J Am Pharm Assoc. 2023; 63: 220-223. DOI: https://doi.org/10.1016/j.japh.2022.12.026

Hill LG, Light AE, Green TC, et al.: Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists. J Am Pharm Assoc. 2023; 63(1): 252-260.e6. DOI: https://doi.org/10.1016/j.japh.2022.08.017

Cote J, Montgomery L: Sublingual buprenorphine as an analgesic in chronic pain: A systematic review. Pain Med. 2014; 15: 1171-1178. DOI: https://doi.org/10.1111/pme.12386

Drug Addiction Treatment Act of 106th United States Congress: 2000. Available at https://www.congress.gov/106/bills/hr2634/BILLS-106hr2634pcs.pdf. Accessed July 9, 2023.

US Substance Abuse and Mental Health Services Administration (SAMHSA): Removal of DATA waiver (X-Waiver) requirement. Available at https://bit.ly/3WuOnkM. Accessed July 9,

Burson J: Buprenorphine regulations. Available at https://bit.ly/3os8EHU. Accessed July 9, 2023.

US State of Tennessee: Tenn. Code Ann. § 53-11-311. Available at https://bit.ly/3H4xwzE. Accessed July 9, 2023.

Tennessee Department of Mental Health and Substance Abuse Services: Tennessee nonresidential buprenorphine treatment guidelines. Available at https://bit.ly/34Ke3SC. Accessed July 9, 2023.

Code of Virginia. § 54.1-3408.4: Prescription of buprenorphine without naloxone, limitation. Expired July 1, 2022. Available at https://bit.ly/3mISsjZ. Accessed July 9, 2023.

Medical Society of Virginia: Opioid and buprenorphine prescriber regulations guide. Available at https://bit.ly/2Ksu7lb. Accessed July 9, 2023.

Kentucky Board of Medical Licensure: 201 KAR 9:260 professional standards for prescribing or dispensing buprenorphine-mono-product or buprenorphine-combined with naloxone. Available at https://bit.ly/3Hn75Xq. Accessed July 9, 2023.

Grande LA: Prescribing the buprenorphine monoproduct for adverse effects of buprenorphine-naloxone. J Addict Med. 2022; 16(1): 4-6. DOI: https://doi.org/10.1097/ADM.0000000000000837

Tsai AC, Kiang MV, Barnett ML, et al.: Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019; 16(11): e1002969. DOI: https://doi.org/10.1371/journal.pmed.1002969

Langabeer JR, Stotts AL, Cortez A, et al.: Geographic proximity to buprenorphine treatment providers in the US. Drug Alcohol Depend. 2020; 213: 108131. DOI: https://doi.org/10.1016/j.drugalcdep.2020.108131

Cicero TJ, Ellisa MS, Chilcoat HD: Understanding the use of diverted buprenorphine. Drug Alcohol Depend. 2018; 193: 117-123. DOI: https://doi.org/10.1016/j.drugalcdep.2018.09.007

Chilcoat HD, Amick HR, Sherwood MR, et al.: Buprenorphine in the United States: Motives for abuse, misuse, and diversion. J Subst Abuse Treat. 2019; 104: 148-157. DOI: https://doi.org/10.1016/j.jsat.2019.07.005

National Institute on Drug Abuse (NIDA): What is the treatment need versus the diversion risk for opioid use disorder treatment? 13 April 2021. Available at https://bit.ly/3krRgWe. Accessed July 9, 2023.

Knopf A: Is naloxone really needed in buprenorphine product? Alcohol Drug Abuse Weekly. 2019; 31(24): 3-4. DOI: https://doi.org/10.1002/adaw.32389

Gregg J, Hartley J, Lawrence D, et al.: The naloxone component of buprenorphine/naloxone: Discouraging misuse, but at what cost? J Addict Med. 2023; 17(1): 7-9. DOI: https://doi.org/10.1097/ADM.0000000000001030

Strickland D, Sorboro J: Adverse effects of regulation on buprenorphine prescribing and its impact on the treatment of opioid use disorder. J Opioid Manag. 2021; 17(7): 133-139. DOI: https://doi.org/10.5055/jom.2021.0650